Background: There are no data on pharmacokinetics, pharmacodynamics, and immunogenicity of intravitreal aflibercept in preterm infants with retinopathy of prematurity (ROP). FIREFLEYE compared aflibercept 0.4 mg/eye and laser photocoagulation in infants with acute-phase ROP requiring treatment. Methods: Infants (gestational age ≤32 weeks or birthweight ≤1500 g) with treatment-requiring ROP in ≥1 eye were randomized 2:1 to receive aflibercept 0.4 mg or laser photocoagulation at baseline in this 24-week, randomized, open-label, noninferiority, phase 3 study. Endpoints include concentrations of free and adjusted bound aflibercept in plasma, pharmacokinetic/pharmacodynamic exploration of systemic anti-vascular endothelial growth factor effects, and immunogenicity. Results: Of 113 treated infants, 75 received aflibercept 0.4 mg per eye at baseline (mean chronological age: 10.4 weeks), mostly bilaterally (71 infants), and with 1 injection/eye (120/146 eyes). Concentrations of free aflibercept were highly variable, with maximum concentration at day 1, declining thereafter. Plasma concentrations of adjusted bound (pharmacologically inactive) aflibercept increased from day 1 to week 4, decreasing up to week 24. Six infants experienced treatment-emergent serious adverse events within 30 days of treatment; aflibercept concentrations were within the range observed in other infants. There was no pattern between free and adjusted bound aflibercept concentrations and blood pressure changes up to week 4. A low-titer (1:30), non-neutralizing, treatment-emergent anti-drug antibody response was reported in 1 infant, though was not clinically relevant. Conclusions: 24-week data suggest intravitreal aflibercept for treatment of acute-phase ROP is not associated with clinically relevant effects on blood pressure, further systemic adverse events, or immunogenicity. ClinicalTrials.gov Identifier: NCT04004208.
Intravitreal (IVT) anti–vascular endothelial growth factor (anti-VEGF) therapies are the standard of care for retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Despite the favourable efficacy and safety profiles of these therapies, decreasing the treatment burden is still an unmet need because frequent injections may be required over many years. The pharmacokinetic and pharmacodynamic properties of IVT therapies, such as ocular half-life and clearance, can affect the duration of VEGF suppression and thus influence clinical outcomes. Although some properties are inherent to the drug molecule (such as molecular weight, binding affinity and potency) and cannot be altered without changing the structure of the molecule, other factors (such as the dose of the drug) can be increased, which may prolong VEGF suppression time in the eye and, in turn, may lead to a more durable effect of the drug. In addition to pharmacokinetic and pharmacodynamic properties, individual patient factors such as age, surgical history and disease status can also affect the pharmacokinetics, pharmacodynamics and observed effectiveness of a drug. This article reviews the key pharmacological properties of IVT anti-VEGF treatments for nAMD and DMO often referred to in the literature, and aims to elucidate their meaning and clinical relevance for managing retinal diseases.
The pharmacokinetics (PK) of a drug determine its systemic exposure and thereby affect its safety and efficacy. The multitude of physiological changes occurring with aging could impact drug absorption, distribution, metabolism or excretion, the key processes how the body is dealing with drugs. Another important, PK-related topic is the risk for relevant drug-drug interactions considering the number of drugs taken concomitantly by elderly patients. At the same time there are examples for relevant differences in the magnitude of drug effects, i.e. the pharmacodynamics of a drug in an aged vs. young population. These could be caused by differences in the number of receptors in the target organ as well as the response to receptor occupation, or by progressive reduction in homeostatic mechanisms, and could affect the efficacy as well as the safety [1]. Such age-related changes in the pharmacodynamics of a drug shall, however, not be addressed in this article despite their proven clinical relevance. When discussing age-related changes in the PK of drugs, and in particular their consequences for dosing recommendations in aged patients, one needs to keep in mind that aging is a gradual, complex and progressive process and that there are no established biological age markers. While there is societal consensus to define elderly as individuals aged 65 years or older [1], dividing elderly in three age groups, such as 65 – 75, 76 – 85, and > 85 might help in better describing the aging processes [2].
30 June 2026 in CPT: Pharmacometrics & Systems Pharmacology
Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in both diseases. In pivotal trials, a high‐dose drug product (AFL‐HD) using a formulation distinct from AFL‐2 and delivering 8‐mg aflibercept every 12 or 16 weeks (following initial monthly dosing) provided visual gains non‐inferior to AFL‐2 administered every 8 weeks (following initial monthly dosing) and comparable safety with fewer injections over 96 weeks. Free and bound aflibercept concentrations in plasma from 2744 participants in 16 clinical trials where aflibercept was administered intravitreally, subcutaneously, or intravenously were analyzed by population pharmacokinetic modeling. A semi‐mechanistic model described the release of free aflibercept from the eye and its target‐mediated elimination from plasma. The evaluated covariates (weight, age, sex, albumin, disease, racial classification, Japanese origin, renal and hepatic functions) resulted in only small numerical differences in systemic exposure. Ocular clearance ( QE ; characterizing the bidirectional transfer of free aflibercept between the eye and central compartment) was comparable across both diseases after adjusting for an age‐dependent decrease. The change in drug product, and not just the dose increase, was responsible for a 39.4% slower QE and extended exposure in the ocular space for AFL‐HD versus AFL‐2. The median ocular concentrations of free aflibercept predicted at the end of the 8‐week dosing interval for AFL‐2 were typically reached 14 weeks after AFL‐HD injections, versus 9–9.5 weeks if QE was identical for both drug products.
22 July 2025 in The Journal of Clinical Pharmacology
According to the FDA Guidance for Industry on Clinical Drug Interaction (DDI) Studies with Combined Oral Contraceptives (COCs), sponsors are expected to conduct dedicated clinical DDI studies if in vitro findings suggest weak or moderate CYP3A induction, while concomitant use of COCs with strong inducers should be avoided. The guidance further suggests that a negative DDI result for drospirenone (DRSP) may be extrapolated to other progestins that are less sensitive to CYP3A modulation, such as levonorgestrel (LNG). This approach assumes that DDI‐mediated changes in exposure directly translate into clinical efficacy across progestins. To evaluate the validity of this assumption, we established a quantitative link between dose, exposure, and response (Pearl Index [PI] and ovulation rate [OR]) via an integrated model‐based meta‐analysis, physiologically based pharmacokinetic, and pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation approach using data from 51 clinical studies in 36,040 women receiving LNG or DRSP. COCs containing LNG and DRSP were selected because they represent clinically relevant progestins at the lower and the upper end of the fraction metabolized via CYP3A4. The results of our analysis show a moderate correlation (Pearson's r = 0.52, 95% CI 0.46‐0.58, P < 0.001) between PI and OR, which enables the use of OR as an ethically measurable endpoint, even at subtherapeutic doses/exposures, to predict efficacy outcomes. They further show that DDI‐induced changes in exposure do not directly translate into clinical response. Therefore, DDIs with COCs should be interpreted in a PK/PD rather than a PK‐only context. The quantitative framework developed in this study can serve as the scientific basis to do so.